Rezolute, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ / shares in Units, shares in Millions					1 Months Ended	3 Months Ended
	Oct. 28, 2020 USD ($) ft²	Oct. 09, 2020 USD ($) $ / shares shares	Oct. 07, 2020	Sep. 15, 2020	Oct. 31, 2020 USD ($)	Sep. 30, 2020 USD ($) $ / shares	Sep. 30, 2019 USD ($)	Oct. 23, 2020 USD ($)
Subsequent Event [Line Items]
Weighted average exercise price \| $ / shares						$ 57.46
Term of warrants						2 years
Reverse stock split, Exchange ratio			0.02
Average monthly rent						$ 59,000	$ 53,000
2021 Financing
Subsequent Event [Line Items]
Transaction fees on gross proceeds and out-of-pocket expenses (in percent)				6.00%
Minimum number of days for happening any other financing				60 days
Additional transaction fees on gross proceeds (in percent)				6.00%
Unpaid incurred offering cost						$ 100,000
Subsequent events
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs (in shares) \| shares		2.5
Number of shares of common stock called by warrants issued \| shares		0.8
Gross proceeds from private placement of equity shares		$ 41,000,000
Net proceeds from private placement		$ 37,500,000
Reverse stock split, Exchange ratio		0.02
Bonus payments					$ 400,000
Lease square feet \| ft²	5,000
Average monthly rent	$ 8,700
Option to renew	true
Renewal term	3 years
Subsequent events \| 2021 Financing
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs (in shares) \| shares		2.5
Weighted average exercise price \| $ / shares		$ 19.50
Term of warrants		7 years
Issue price per unit \| $ / shares		$ 16.50
Gross proceeds from private placement of equity shares		$ 41,000,000
Transaction fees		2,500,000
Costs for professional fees and other financing costs		$ 1,000,000
Percent of estimated costs for professional fees and other offering costs		6.00%
Liquidated damages on gross proceeds (in percent)		6.00%
Number of warrants issued for shares \| shares		0.8
Aggregate bonus payments approved		$ 1,000,000
Reverse stock split		one share for 50 shares
Subsequent events \| Xoma
Subsequent Event [Line Items]
Gross proceeds from private placement of equity shares		$ 20,000,000			$ 41,000,000
Subsequent events \| Xoma \| License agreement
Subsequent Event [Line Items]
Acceleration of the remaining balance due								$ 1,400,000
Subsequent events \| Activesite Pharmaceuticals Inc
Subsequent Event [Line Items]
First milestone payment due after completion of the preclinical work	$ 1,000,000